Free Trial
NASDAQ:ONC

BeOne Medicines 4/1/2026 Earnings Report

BeOne Medicines logo
$315.16 -1.84 (-0.58%)
As of 01:21 PM Eastern
This is a fair market value price provided by Massive. Learn more.

BeOne Medicines EPS Results

Actual EPS
$0.25
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

BeOne Medicines Revenue Results

Actual Revenue
$1.51 billion
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

BeOne Medicines Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

BeOne Medicines Earnings Headlines

BeOne Medicines Shares Surge After Robust First-Quarter
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses an emerging potential $10 trillion technology backed by Elon Musk and Sam Altman. This breakthrough could completely replace our need for foreign oil - and send one small group of stocks soaring in the process.tc pixel
See More BeOne Medicines Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BeOne Medicines? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BeOne Medicines and other key companies, straight to your email.

About BeOne Medicines

BeOne Medicines (NASDAQ:ONC) Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

View BeOne Medicines Profile